See more : Yeah Yeah Group Holdings Limited (8082.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Aeglea BioTherapeutics, Inc. (AGLE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeglea BioTherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CH. Karnchang Public Company Limited (CK.BK) Income Statement Analysis – Financial Results
- Rogers Communications Inc. (RCI-A.TO) Income Statement Analysis – Financial Results
- Powszechny Zaklad Ubezpieczen SA (PZU.WA) Income Statement Analysis – Financial Results
- Coca-Cola Europacific Partners PLC (CCEP.AS) Income Statement Analysis – Financial Results
- Prosperous Industrial (Holdings) Limited (1731.HK) Income Statement Analysis – Financial Results
Aeglea BioTherapeutics, Inc. (AGLE)
About Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Other Expenses | -7.00K | -122.00K | -5.00K | -63.00K | -57.00K | -42.00K | -36.00K | -2.00K | 0.00 |
| Operating Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Cost & Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 837.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.57M | 1.58M | 996.00K | 418.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -84.78M | -65.65M | -80.49M | -80.33M | -44.06M | -27.68M | -21.77M | -11.23M | -7.44M |
| EBITDA Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,133.10% | -531.72% | -470.48% | -184.49% | 0.00% |
| Operating Income | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | 830.00K | -11.00K | 588.00K | 2.08M | -57.00K | -42.00K | -36.00K | 20.00K | -1.44M |
| Income Before Tax | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -136.00K | 141.00K | -593.00K | -2.56M | -57.00K | -731.00K | -244.00K | -22.00K | 1.44M |
| Net Income | -83.82M | -65.80M | -80.30M | -75.69M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| EPS Diluted | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| Weighted Avg Shares Out | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
| Weighted Avg Shares Out (Dil) | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
5 Top Penny Stocks To Watch With News Before Next Week
Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
Buying Penny Stocks Right Now? 3 to Watch This Week
4 Penny Stocks To Watch With Bullish Buys From Options Traders
Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates
Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports